The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen CEO Dr. Shankar Musunuri presented the company’s novel modifier gene therapy platform and three investigational assets currently in Phase 3 trials at the Stifel 2026 Healthcare Conference in New York City.
The update provides insight into Ocugen’s ongoing clinical development efforts in the biotechnology sector, emphasizing its strategy to advance late-stage gene therapy products.
View post on X Loading...
Ocugen recently announced a modifier gene therapy that uses master regulator genes to target major blindness diseases through network effects, according to a company statement. The firm also signed a licensing agreement with Roots Pharmaceutical valued at up to $259 million in milestones and royalties for its OCU400 asset in the MENA region, as detailed in a previous deal disclosure. These moves support Ocugen’s current late-stage gene therapy focus.